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Abstract
There is a great need for innovative technologies that will improve the health and quality of life (QoL) of Polish 
patients with cardiac problems. It is important that the safety and effectiveness of the technology are confirmed 
by scientific evidence on which guidelines and clinical recommendations are based. Scientific evidence for 
medical devices is also increasingly important for decision-making in finance approval from public funds. New 
technologies in cardiology and cardiac surgery contribute to improved patient QoL, increased treatment effec-
tiveness and facilitated diagnosis. Hence, it is necessary to increase accessibility to such technologies, primarily 
through the development of clinical recommendations, and education of medical personnel in conjunction with 
public funding. The aim of this publication is to present the recommendations of leading experts in the field of 
cardiology and cardiosurgery, supported by clinical research results, regarding the use of the cited innovative 
medical technologies and solutions leading to their increased availability for Polish patients. (Cardiol J 2019;  
26, 2: 114–129)
Key words: coronary angioplasty, optical coherence tomography, heart failure, implantable 
loop recorder, mitral regurgitation, ventricular assist system, pulmonary artery pressure
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Introduction
New technologies in cardiology and cardiac 
surgery contribute to the improvement of quality 
of life (QoL) for patients by increasing the effec-
tiveness of treatment and facilitating diagnostics. 
Therefore, if possible, striving to increase their 
accessibility primarily through the development of 
clinical recommendations, the education of medical 
personnel and public funding is paramount. Avail-
able guidelines of conduct, although very compre-
hensive, are constantly updated, and need to be 
supplemented in certain areas where innovative 
solutions can be applied.
Cardiovascular disease causes 45% of deaths 
in Poland (180,000 a year), while cancer comprises 
26% of deaths. Due attention from a patient mortal-
ity perspective requires national health policy to 
be taken into account  [1, 2]. There is, therefore, 
a great need for new innovative technologies that 
will improve the health and QoL of Polish patients 
with cardiac problems.
Unfortunately, the system at present sig-
nificantly hinders the incorporation of innovative 
non-drug technologies into a basket of guaranteed 
services that has not adapted to medical progress. 
The costs of innovative medical technologies could 
be calculated in a new way. Nowadays, the cheap-
est procedures with immediate costs (direct) are 
chosen by the payer. However, additional costs, 
such as the cost of the treatment of subsequent 
complications, additional hospitalization and medi-
cine, dismissal due to an inability to work, social 
welfare and sickness allowances and other costs are 
borne by a budget and patients are not taken into 
account. The choice of medical technology should 
be guided by an overall cost, and not just a greater 
temporary benefit through financing [3]. 
These recommendations are based on pres-
entations and discussions that were held during 
Advisory Board meetings, which took place in 
cooperation with the ‘Quo Vadis Cardiology?’ 
initiative. Data collected during a questionnaire 
study which was conducted by the Arcana Institute 
are supported by clinical research results. The 
aim was to gather the opinions of leading experts 
(14 experts) in the field of conservative cardiology, 
interventional cardiology, electrophysiology and 
cardiac surgery for guidelines on the use of inno-
vative medical technologies and solutions leading 
to increasing their availability for Polish patients.
The guidelines and recommendations pre-
sented apply to the following medical technologies:
 — left ventricular assist systems/devices (LVAS/ 
/LVAD); e.g. HeartMate (HM) 3, HeartWare, 
BerlinHeart, TerumoHeart;
 — a system for percutaneous repair of mitral 
regurgitation (MitraClip);
 — a heart failure (HF) system for pulmonary 
artery pressure measurement (CardioMEMS);
 — implantable loop recorders (ILR); e.g. Confirm 
Rx, Reveal DX and XT;
 — optical coherence tomography (OCT).
Heart failure
Heart failure has become a realized epidemic 
of the 21 century. Almost 80% of cases result from 
coronary heart disease, which is accompanied by 
hypertension in 53% of cases. The remaining cases 
are the result of hypertension and other heart dis-
eases. Heart disease has been a more frequent cause 
of death than cancer in Poland for many years (over 
50% of deaths, amounting to approximately 60,000 
deaths per year). This fact requires due attention 
when taking Poland’s health policy into account [1, 2].
Currently, the number of patients at various 
stages of HF severity in Poland amounts to ap-
proximately 800,000 people [2]. Forecasts indicate 
that in 10 years this number will have increased 
by approximately 25%. A total of 60,000 people 
die each year due to HF and close to 150,000 are 
hospitalized [2]. HF hospitalization rates in Poland 
are among the highest in Europe (547/100,000 in-
habitants) and unfortunately, despite the progress 
in treatment, the numbers have not changed sig-
nificantly over the last 5 years (from 2008 to 2013). 
They are two times higher than in the Organiza-
tion for Economic Co-operation and Development 
(OECD) countries and 5 times higher than in the 
United Kingdom. Total indirect costs of HF in 
Poland have been estimated to be approximately 
4 billion PLN per year. Taking into account Na-
tional Health Fund expenditure on treatment of 
HF at the level of approximately 900 million PLN 
in 2016, indirect costs of this disease in Poland 
are more than 4 times higher than direct medi-
cal costs [2]. This is primarily a consequence of 
the lack of effective medical technologies, not to 
mention a comprehensive model for patient care. 
HF is currently one of the largest unmet medical 
needs in Poland.
Methods of treatment
The treatment of HF aims to stop or reverse 
myocardial dysfunction, control symptoms and 
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reduce mortality.  The choice of treatment depends 
on the type/cause of HF and clinical status of the 
patient [4]. If treatment options are exhausted, only 
heart transplantation (HTx) and mechanical circula-
tory support remain. HTx is currently one of the 
best methods of treatment of extreme HF, enabling 
long-term survival. Currently, the estimated annual 
survival for patients qualified for urgent cardiac 
transplant is < 50%, while after HTx, it is 50% 
over a 10-year period. Annually, approximately 5000 
transplantations are performed worldwide, 2000 in 
the United States and nearly 1500 in Europe. The 
number of candidates for HTx is estimated to be 
10 times higher. About 80–100 HTx are performed 
every year in Poland, while the demand is about 
4 times higher [5]. The basic problem in transplan-
tology is the limited number of organ donors. In 
addition, HTx is associated with a high frequency 
of appointments at an outpatient clinic and a long 
procedure. There is, therefore, an urgent need to look 
for other methods to support a damaged heart that 
would provide a longer survival time while waiting 
for HTx. The implantation of the ventricular assist 
system is a procedure that is performed in patients 
with severe and reversible (or irreversible) heart 
damage, in whom alternative treatment options have 
been exhausted, i.e. no other cardiac surgery is pos-
sible, and pharmacological treatment is not expected 
to stop further progression of the disease. Mechanical 
circulatory support devices are designed to support 
the work of the left (LVAD) or right (RVAD) ventri-
cle. The use of ventricular assist device (VAD) was 
included in the 2016 European Society of Cardiology 
(ESC) Guidelines for the diagnosis and treatment of 
acute and chronic HF (Fig. 1) [6].
Clinical evidence
Details about clinical evidence — see Table 1 
[7–18].
Other methods of treatment  
and their comparison with HM3
 — Other systems for mechanical circulatory 
support (MCS) — without ‘artificial pulse’ in 
comparison to HM3;
 — External pump supporting the left ventricle 
and devices for extracorporeal oxygenation 
of the blood (ECMO) — disadvantages: no 
possibility of functioning at home, need for 
greater medical supervision:
• HM3 — the complexity of supplying solu-
tions to patients  with HF — the possi-
bility of waiting quietly for improvement 
of the left ventricular function or surgical 
treatment, the possibility of long-term 
use (also in an outpatient mode);
 — Conservative treatment — disadvantages: 
higher frequency of appointments at an outpa-
tient clinic, limited availability, longer duration 
of the procedure:
• HM3 — greater patient survival.
Reimbursement and economic effectiveness
The economic analysis based on 2-year results 
from the MOMENTUM 3 study indicated that use 
of the HeartMate 3 pump reduced re-hospitaliza-
tions and the number of days for re-hospitalization 
and therefore contributed to a significant reduction 
in treatment costs compared to the HeartMate 2 
pump [18].
In England, the expense is covered publicly 
and includes all the costs of providing the ser-
Figure 1. HeartMate — left ventricular assist system 
(LVAS). This is the latest third generation pump (LVAD) 
with continuous blood flow, which is used for long-term 
cardiac support of patients suffering from severe heart 
failure as part of bridging therapy: for transplantation, 
for recovery or for candidacy/decision and as a target 
therapy. In the HeartMate 3 pump, the rotor is sus-
pended in an electromagnetic field, thanks to which, 
the spaces which are not washed away by blood are 
removed and the occurrence of thromboembolic com-
plications eliminated. A characteristic feature of this sys-
tem is its ability to quickly change the flow rate (every 
2 s), which can produce a rise of pulsation, or imitate 
natural blood flow.
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vice, costs of hospitalization, diagnostic tests, 
medical devices and medicines. In Australia, ser-
vices are provided as part of hospitalization are 
settled within the framework of the Diagnosis 
Related Groups (DRG) group funding system. 
A similar situation is present in New Zealand and 
Estonia. In Greece, funding is based on KEN-
DRG groups (a combination of cost estimates 
from selected public hospitals and the ‘imported’ 
cost weight). In Germany, hospitalizations for the 
implementation of a cardiac support procedure are 
financed on the basis of the G-DRG system. In 
Croatia, under the public system, patients are re-
quired to pay 25% of the value of services provided 
as part of hospitalization and 40% of the value of 
services in an outpatient mode. The highest cost of 
implanting artificial chambers is observed in New 
Zealand, and the lowest, in Germany.
The cost of implanting artificial heart chambers, 
according to National Health Fund, ranges from 
126,601 PLN to 375,207 PLN [19]. According to an 
analysis of impact on the organization of the health-
care system carried out by Agency for Health Tech-
nology Assessment and Tariff System (AOTMiT), 
financing the implantation of VAD pumps will re-
sult in a reduction of costs in this area. Potential 
savings will result from the fact that the patient 
treatment processes are conducted in outpatient 
mode at home, in contrast to patients treated with 
external pumps who are permanently hospitalized. 
Savings resulting from a reduction in medical costs 
could be allocated to other benefits. In addition, 
a comprehensive care model for patients with VAD 
can provide them with optimal supervision and 
treatment, which will certainly translate into an 
improvement of treatment results, the reduction 
of serious complications and mortality [4].
Expert recommendations
Experts indicated that using HM3 will contrib-
ute to an improvement in patient survival, QoL, 
treatment efficiency, the reduction of treatment 
costs and reduction in occurrence of adverse car-
diovascular events.
Experts also pointed out that using HM3 
will primarily affect not only a reduction in the 
number of patient hospitalizations, a reduction in 
additional procedures and diagnostic tests, but also 
a reduction in the need for medications. In Poland, 
approximately 100 heart pump insertions should be 
performed per year, which would satisfy the needs 
of patients. About 46 pumps are implanted every 
year in Poland (these are mainly HM3 pumps). The 
highest benefit from HM3 is received by patients 
in the INTERMACS 3 and 4 class. These are 
outpatients who stay at home and are not treated 
in hospital. These are also patients with normal 
right ventricle and no pulmonary hypertension, i.e. 
patients with a low risk of complications.
From the patient perspective using heart 
assist pumps as a target therapy is beneficial 
because it significantly improves QoL. The use 
of these pumps is important to the payer because 
it reduces the number of patient hospitalizations, 
procedures diagnostic tests, and additionally de-
creases the need for medicine. Periodical infections 
which occur due to using a power cord, may lead to 
a need for removal of the heart pump. In this case, 
the patient is referred for heart transplant. There-
fore, an appropriate selection for a cardiac surgery 
center where cardiac transplants are performed 
requires recommendations for such an indication. 
Work is underway to construct a pump that will 
not require the use of an external power cord. In 
this case, implantation of this pump could be used 
as a target therapy.
Heart assist pumps should only be implanted 
in transplant centers. In this type of center, a full 
treatment profile should be available: all treatment 
options are in one place and comprehensive patient 
care is provided.
In Poland, the same services are performed 
during the implantation of a cardiac support pump 
as during HTx (a patient’s qualification for the 
pump or transplant is the same). There is no pro-
cedure that would cover the cost of hospitalization 
after implantation of a heart pump. There is also 
a need to create a system for the comprehensive 
care for a patient with an LVAD.
In order to broaden patient access to HM3, 
experts first of all point to a need for adequate 
public funding, equipping clinical centers (apart 
from the technology itself) and increasing the 
level of awareness of the technology in the medical 
environment. The need for increased awareness 
about the availability of HM3 is also connected with 
a low level of awareness of this technology among 
physicians, especially primary care physicians. 
They mainly recommend drugs to young patients 
with HF, although they are eligible candidates for 
LVAD implantations.
Mitral regurgitation
Mitral regurgitation (MR) is currently the 
second most common valve defect in Europe [20]. 
The frequency of this defect increases with age 
and it is estimated that there are currently 2–2.5 
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million people suffering from MR in the United 
States, and this number will double by 2030 due 
to an increase in size of the aging population [21]. 
The treatment of isolated mitral leaflet repair us-
ing the ‘edge-to-edge’ method was introduced in 
1991 by Alfieri to repair prolapse of the anterior 
mitral leaflet [22]. The operation consists of sew-
ing both mitral leaflets in the central part in order 
to increase contact of the anterior and posterior 
leaflets, which leads to a reduction of regurgita-
tion. This technique is also useful in the loss of the 
posterior or both leaflets. A double orifice mitral 
valve, which is obtained through this procedure, 
does not usually cause narrowing of the mitral 
outlet, even in combination with annuloplasty, and, 
as a result, its surface area is reduced. This is the 
basis for the method of percutaneous treatment of 
MR (MitraClip) (Fig. 2) [21].
MitraClip is usually used to treat people with 
severe, post-infarction heart disease. In Europe, 
it is estimated that almost 1% of the population 
struggles with functional MR that results from 
a left ventricle defect after heart attacks or primary 
cardiomyopathy. In Poland, the figure amounts 
to approximately 400,000 people. Unfortunately, 
there are still far too few MitraClip procedures, 
due to a limited reimbursement by the National 
Health Fund. The MitraClip device reaches a price 
of approximately 80,000 PLN. However, the cost 
of long-term, repeated patient hospitalizations are 
comparable [23]. 
The MitraClip system has been used around 
the world since 2008. In Poland, only 9 centers 
perform procedures using MitraClip, which limits 
the frequency of this treatment in our country. 
A procedure using the MitraClip system, as a method 
of repairing heart valve leaflets, should be per-
formed only at highly specialized centers. 
Clinical evidence
Clinical trials have demonstrated the efficacy 
and safety of using MitraClip for percutaneous 
repair of MR. This was also confirmed on the basis 
of data from registers (Table 2) [24–28].
MITRA-FR, the first randomized, controlled 
trial of the percutaneous clip coaptation in degen-
eration of the mitral valve, showed no benefit of the 
MitraClip in addition to optimal medical care [29]. 
Over a 12-month period, 152 patients randomized 
to treatment with MitraClip experienced improve-
ments of the MR grade and New York Heart As-
sociation (NYHA) class, but similar improvements 
were also seen in the 137 patients treated with 
optimal medical therapy. Over 12 months, the 
primary composite endpoint of all-cause death 
and unplanned re-hospitalization for HF had no 
significant difference between groups: 54.6% in the 
intervention group and 51.3% in the control group 
(odds ratio [OR] 1.16; 95% confidence interval [CI] 
0.73–1.84). The limitation of the MITRA-FR study 
was that patients in the optimal medical care arm 
were not optimized before the trial, hence adjust-
ments were performed after the trial had started. 
The results of another randomized clinical 
trial, COAPT, in which 78 centers from the United 
States and Canada participated, showed a clear 
clinical efficacy of MR treatment with the use of 
MitraClip [30]. The COAPT trial is a United States 
Investigational Device Exemption, which was de-
signed for Food and Drug Administration (FDA) 
approval of MitraClip for secondary MR. Patients 
with HF, in whom MR develops secondary to left 
ventricular dysfunction, have a poor prognosis, 
with reduced QoL, frequent hospitalizations due to 
HF and decreased survival. There are no proven 
therapies for secondary MR in HF. Guideline-
directed medical therapy and cardiac resynchro-
Figure 2. MitraClip — a system for percutaneous repair 
of mitral regurgitation. The MitraClip system is used 
for percutaneous repair of mitral valve mitigation of 
the beating heart as an alternative to conventional car-
diac surgery. The procedure is performed in a suit-
ably adapted hemodynamic laboratory using transeso-
phageal echocardiography and fluoroscopy [21]. The 
MitraClip system consists of an implant, an introductory 
catheter and an implant placement system that enables 
it to be placed on the mitral valve leaflet, causing it to 
be permanently approached, and a double-mitral valve 
is formed, thereby preventing blood from regressing. 
MitraClip is introduced into the mitral valve outlet via 
the venous system (femoral vein, inferior vena cava 
and then, after puncturing the atrial septum, to the left 
atrium) without opening the chest.
www.cardiologyjournal.org 121
Dariusz Dudek et al., Recommendations on the use of innovative medical technologies in cardiology and cardiac surgery
nization therapy may provide only symptomatic 
relief in some patients.
In this parallel-controlled, open-label, multi-
center trial, 614 patients with HF and moderate-
to-severe or severe secondary MR, who remained 
symptomatic despite the use of maximal doses of 
guideline-directed medical therapy, were enrolled. 
Patients were randomly assigned to transcath-
eter mitral-valve repair (MitraClip) plus medical 
therapy (device group) or medical therapy alone 
(control group). The annualized rate of all hos-
pitalizations due to HF within 24 months was 
35.8% per patient-year in the device group, com-
pared with 67.9% per patient-year in the control 
group (hazard ratio [HR] 0.53; 95% CI 0.40–0.70; 
p < 0.001). The rate of cases that were free 
from device-related complications at 12 months 
was 96.6% (lower 95% confidence limit, 94.8%; 
p < 0.001 for comparison with the performance 
goal). Death from any cause within 24 months 
occurred in 29.1% of patients in the device group 
compared with 46.1% in the control group (HR 
0.62; 95% CI 0.46–0.82; p < 0.001). All-cause 
mortality within 24 months was significantly lower 
with device-based treatment than with medical 
therapy alone (29.1% vs. 46.1%; HR 0.62; 95% 
CI 0.46–0.82; p < 0.001). The number of patients 
needed to be treated to save one life within 24 
months was 5.9 (95% CI 3.9–11.7) in the device 
group.
One possible reason for different outcomes 
between the MITRA-FR and COAPT studies was 
that in MITRA-FR, among the patients that were 
receiving HF medicines at baseline, variable ad-
justments in each group during a follow-up in 
comparison to ‘real-world’ practice was allowed. In 
the COAPT study, the Clinical Events Committee 
confirmed patients for whom maximally-tolerated 
guideline-directed medical therapy was not effec-
tive at baseline and there were few major changes 
during a follow-up. What is more, the procedural 
complications rate in MITRA-FR was almost 2 times 
higher than in the COAPT study (14.6% vs. 8.8%).
In this patient group, the use of MitraClip 
resulted in a lower rate of hospitalizations due to 
HF and lower all-cause mortality within 24 months 
of follow-up in comparison to medical therapy 
alone, while maintaining a very high rate of cases 
that were free from device-related complications 
[30]. As such, MitraClip was the first therapy that 
was shown to improve the prognosis of patients 
with HF by reducing secondary MR due to left 
ventricular dysfunction. Therefore, if MitraClip is 
the first-line therapy, it improves the prognosis of 
patients with HF by reducing secondary MR due 
to left ventricular dysfunction.
Reimbursement and economic effectiveness
As part of an economic analysis performed 
by AOTMiT, the use of MitraClip technology was 
compared with symptomatic pharmacological treat-
ment as the only available therapeutic option in the 
target group of patients [31]. The results of the 
analysis indicated that the use of MitraClip tech-
Table 2. Summary of main results of studies and registries assessing efficacy and safety of the MitraClip 
system for percutaneous repair of mitral regurgitation [24]. In clinical trials and in medical practice 
(registry data), in patients with high operational risk (mean age 74–82), the MitraClip system for percu-
taneous repair of mitral regurgitation was associated with very high clinical efficacy (86–100%), which 
translated into an absence of death, cardiac surgeries or reoperations. The annual mortality after Mitra-
Clip implantation was low and ranged from 15% to 26%. In addition, the MitraClip system made it possible 
to achieve a low rate of hospitalizations due to heart failure within 1 year after surgery (7–23%) [24–28]. 
Study Age  
[years]
DMR  
[%]
Acute success 
[%]
1-year mortality  
[%]
One-year HF  
hospitalization [%]
STS/ACC TVT 82 85.9 92.8 25.9 20.2
SENTINEL 74 28 95.4 15.3 22.8
ACCESS-EU 74 20.6 91.7 19.2 19.8
EVEREST II HRS* 76 29.9 86 22.8 –
EVEREST PR** 82 100 95.3 23.6 18
GRASP 72 23.9 100 16.2 7.1
TRAMI 76 93.8 97 20.3 14.1
MITRA Swiss 77 38 85 15.4 –
DMR — degeneration of the mitral valve, HF — heart failure; *HRS — high surgical risk cohort, **PR — percutaneous repair cohort
122 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 2
nology provides better clinical effects compared to 
pharmacotherapy. Both the expected survival time 
and the quality-adjusted life years were prolonged. 
The ratio of additional costs to additional effects 
indicated that the use of MitraClip technology was 
cost-effective, i.e. it provided additional clinical ef-
fects at an acceptable additional cost. In a 10-year 
time horizon, the average cost of an additional 
year of life (when using MitraClip, compared to 
pharmacotherapy) is 36,502 PLN, and the average 
cost of an additional quality-adjusted year is 47,853 
PLN, thus clearly below the profitability threshold 
(105,801 PLN).
Expert recommendations
In 2017, 140 treatment procedures were per-
formed using the MitraClip system. However, this 
figure is still too low in relation to demand, while 
at the same time there is a continuous increase in 
the number of valvular interventions in Poland.
According to experts, there should be 10–20 
centers that perform treatment with the use of 
MitraClip, this treatment includes refunds for pa-
tient transport to the center (declarations based on 
epidemiological data). Qualification and treatment 
should be carried out only at highly specialized 
centers.
Hemodynamic monitoring
Pulmonary artery (PA) pressure monitoring 
provides earlier detection of HF progression than 
other markers (i.e. patient weight, symptoms, 
blood pressure) [32]. PA pressure measurement, 
along with biochemical markers, have become the 
standard tools for managing all forms of HF. In 
combination with clinical symptoms, PA pressure 
measurement provides a rational basis for the 
choice of drug dosage. 
The CardioMEMS system consists of an implant-
able wireless sensor with an introductory catheter, 
an electronic patient system, and a patient database 
for clinical review. The sensor is implanted using 
known catheter deployment methods and remains 
implanted for the rest of the patient’s life. It does not 
have wires, generators or batteries which require 
replacement. The CardioMEMS system for pulmo-
nary hemodynamic monitoring was approved by the 
FDA in 2014 and received a Conformité Européenne 
(CE) mark in 2011. It provides measurement of PA 
pressure non-invasively anytime and anywhere, ena-
bling  quick adjustments of therapy. A 15 × 3.5 mm 
CardioMEMS sensor is implanted into the lu-
men of the PA. Measurements are sent wirelessly 
via a transmitter, and the system is able to monitor 
PA pressure. The important thing to note is that the 
increase of intracardiac pressure and PA pressure pre-
cedes HF decompensation by several days. The PA 
CardioMEMS sensor provides non-invasive pressure 
data (PA waveform, systolic, diastolic, and moderate 
arterial pressure and heart rate). CardioMEMS pro-
vides direct PA pressure measurement and avoids 
the disadvantages associated with PA catheters and 
impedance measurements. Patients send information 
about daily pressure or as recommended, and this 
information is transmitted to a secure website. If the 
PA pressure exceeds set threshold values, clinicians 
are automatically informed.
CardioMEMS is indicated for patients with 
HF class III according to NYHA, who were hos-
pitalized due to HF in the previous year. It is 
not recommended for patients who cannot take 
dual antiplatelet or anticoagulant medications for 
a month subsequent to PA sensor implantation.
The recommendation of the CardioMEMS 
system is included in the 2016 ESC Guidelines for 
the diagnosis and treatment of acute and chronic 
HF in symptomatic patients with HF, who had been 
previously hospitalized due to HF, thereby reducing 
the risk of rehospitalization (class IIb) [6].
Clinical evidence
Detail about clinical evidence — see Table 3 
[33, 34].
Reimbursement and economic effectiveness
Currently, the CardioMEMS device is not fi-
nanced from public funds in Poland. In clinical trials 
and on the basis of registry data in the United States, 
the use of the CardioMEMS system contributes to 
a significant reduction in the frequency of hospitaliza-
tion and mortality, this directly translates into a reduc-
tion of costs associated with the treatment of HF [34].
Monitoring of heart rhythm disorders
Most cardiac arrhythmias can be diagnosed 
using standard ECG or Holter monitoring, but in 
some cases, arrhythmia is elusive and presently it 
was only suspected as a mechanism of the uncon-
sciousness. Sometimes rhythm disorders occur so 
rarely that they cannot be predicted or triggered. 
In such cases, an ILR is required. The primary 
indication for ILR implantation is the diagnosis of 
syncope. It can also be used to differentiate heart 
palpitations of a symptomatic character that are 
rare: the records received enable a differentiation 
of sinus, ventricular and supraventricular tachycar-
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dias. ILR can also be used to monitor heart rhythm 
in patients before and after ablation treatment due 
to atrial fibrillation. The use of ILR is indicated in 
the ESC Guidelines:
 — 2009 and 2018 — regarding the diagnosis and 
management of syncope [35, 36];
 — 2015 — concerning the management of pa-
tients with ventricular arrhythmias and the 
prevention of sudden cardiac death [37];
 — 2016 — for the treatment of atrial fibrilla- 
tion [38].
In the latest ESC Guidelines from 2018, indi-
cations for the use of ILR have been extended to 
patients [36]:
 — with suspected anecdotal epilepsy;
 — who experience unexplained falls;
 — with primary cardiomyopathy or inherited 
arrhythmogenic disorder, who are at low risk 
of sudden cardiac death, as an alternative to 
implantable cardioverter-defibrillator (ICD).
The new guidelines emphasize the role of 
long-term diagnosis in the absence of a documented 
cause of syncope, and ILR value has gained a new 
class of indications, namely IA.
Confirm Rx is an under-the-skin implantable 
long-lasting heart rate recorder, which is currently 
the only one in the world with Bluetooth technol-
ogy. Thanks to this, it connects directly to the pa-
tient’s smartphone, which eliminates the need for 
a handy event recorder and a stationary transmitter. 
Through this technology, the recording of an abnor-
mal heart rhythm can be immediately sent to the 
central control system, where data are stored and 
then analyzed by a doctor, who takes appropriate 
action depending on the cause of the symptoms. 
The advantage of Confirm Rx is the small size of 
the device (the pursuit of miniaturization) and only 
a few dozen seconds of procedure, which makes it 
possible to implant the device in a treatment room. 
The procedure is carried out in the subcutaneous 
area and enables long-term diagnostics. Confirm Rx 
is the simplest and easiest to implant device among 
the devices of this type available on the market. 
The first ILR implantation in Poland was car-
ried out in 2015 (it was not Confirm Rx but another 
device, without Bluetooth technology) [39]. The 
first implantation of the Confirm Rx recorder in 
a child recently has been done. Such devices are 
Table 3. Characteristics and main outcomes of clinical trials assessing the effectiveness and safety  
of CardioMEMS. CardioMEMS is the first and only Food and Drug Administration-approved heart fail-
ure (HF) monitoring system that significantly reduces the number of HF hospitalizations and improves 
quality of life and physical performance. In clinical trials, the use of the CardioMEMS system for  
pulmonary artery (PA) measurement reduced hospitalizations by 33% over an average period of  
18 months. CardioMEMS is an economical way to control the condition of patients with New York Heart 
Association HF class III. In Poland, work is currently underway to prepare for the first implantation of 
the device.
CHARACTERISTICS
Study Study type Population Intervention Comparator Outcomes
CHAMPION [33] Randomized  
clinical trial
HF CardioMEMS No PA  
monitoring
Frequency of  
hospitalizations  
associated with HF
MEDICARE  
registry [34]
Real-world data HF CardioMEMS – Hospitalisation due to 
HF and mortality
Desai et al. [34] Real-world data HF CardioMEMS – –
RESULTS
Study Frequency of hospitalizations associated with HF Mortality Costs
CHAMPION 6-months: 30% reduction compared to control – –
Observation period: 39% reduction compared  
to control (p < 0.0001)
MEDICARE  
registry
24% reduction 1-year: 30%  
reduction
–
Desai et al. 5 months: 45% reduction Significant reduction 
in costs associated 
with HF treatment
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currently not reimbursed in Poland. Confirm Rx 
is currently under reimbursement procedure in 
France. In Germany, mHealth (mobile health — 
services related to telemedicine) have independ-
ent funding. Many countries, including the United 
States, are implementing a procedure to increase 
the availability of this technology for their patients.
Clinical evidence
The location of ILR devices in the ESC Guide-
lines and the widening of the indications for their 
use has support in the results of many randomized 
clinical trials showing a significant advantage of 
ILR over standard diagnostics. In a meta-analysis 
of 5 randomized clinical trials, which are pre-
sented in the ESC 2018 Guidelines on diagnosis 
and management of syncope, 660 patients with 
unexplained syncope were randomized to stand-
ard management (external loop recorders, incline 
test, electrophysiological study) or extended 
monitoring with ILR [36]. The result showed that 
the use of ILR increased by almost 4 times the 
chance of diagnosing unexplained cases of syncope 
compared to the standard procedure (relative risk 
[RR]) 3.7; 95% CI 2.7–5.0; p = 0.001). Statistical 
analysis carried out by the authors of the study 
showed the statistical significance of the results 
obtained. In patients with a bundle branch block 
in whom the atrioventricular block is likely to oc-
cur despite a negative complete electrophysiology 
study, arrhythmia was observed in 41% of these 
patients (70% atrioventricular blocking) due to 
ILR monitoring, based on a pooled analysis from 
3 clinical trials [36]. In patients who were sus-
pected of epilepsy, but treatment turned out to be 
ineffective, results of a pooled analysis of clinical 
trials showed that the attack was documented by 
ILR in 62% of patients, with 26% of the patients in 
whom it was caused by arrhythmias [36]. Among 
patients with unexplained falls, the results from 
a pooled analysis of clinical trials showed that the 
attack was documented by ILR in 70% of patients, 
with 14% of patients in whom it was caused by 
arrhythmia.
Other diagnostic methods used to monitor 
heart disorder and their comparison with 
Confirm Rx™
 — Other subcutaneous implantable recorders 
(Reveal, BioMonitor 2):
• CRx — additional features, e.g. Bluetooth 
communication;
 — Telemonitoring/smartphone applications con-
nected with an external device:
• CRx — possible diagnosis of the type of 
arrhythmias (similar to a pacemaker);
 — Electrocardiography:
• CRx — usually makes it possible to give 
a final diagnosis;
 — External recorders (including loop):
• CRx — independent from patient, long-
term, constant monitoring; diagnostic ef-
ficiency;
 — Holter;
 — Implantable pacemakers and defibrillator 
(ICD).
Reimbursement and economic effectiveness
These devices, which are used to detect 
asymptomatic arrhythmias and conduction dis-
orders, are not currently reimbursed in Poland. 
Confirm Rx is currently under reimbursement 
procedure in France. In Germany, mHealth (mobile 
health — services related to telemedicine) have 
independent funding. Most countries, including 
the United States, are implementing a procedure 
to increase the availability of this technology for 
their patients.
In a randomized clinical trial of syncope as-
sessment (‘Cost Implications of Testing Strategy 
in Patients with Syncope’), it was concluded that 
a strategy of prolonged monitoring with implant-
able recorders is a more cost–effective and efficient 
diagnostic approach than conventional testing in 
patients with recurrent, unexplained syncope and 
preserved left ventricular function. The strategy of 
primary monitoring significantly reduced the cost 
by $2016 (p = 0.002) [40]. 
In a randomized study in the early use of an 
ILR syncope evaluation (FRESH study), it was con-
cluded that in patients with unexplained syncope, 
the early use of an ILR had a superior diagnostic 
yield in comparison to the conventional strategy, 
with lower healthcare-related costs [41]. 
In a randomized Diamantopoulos 2016 study, it 
was concluded that insertable cardiac monitors are 
a cost–effective diagnostic tool for the prevention 
of recurrent stroke in patients with a cryptogenic 
stroke [42]. 
In a randomized Giada 2007 study, despite 
the higher initial cost, the cost per diagnosis in 
the ILR group was lower than in the conventional 
strategy group (€3056 ± €363 vs. €6768 ± €6672, 
p = 0.012) for diagnosis of recurrent unexplained 
palpitations [43]. 
In a Davis 2012 study, ILR monitoring was 
found to be a likely cost–effective strategy for 
patients in the United Kingdom National Health 
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Service, who had experienced infrequent episodes 
of transient loss of consciousness, which had either 
remained unexplained or were suspected to be of 
arrhythmia-origin after an initial assessment and 
specialist cardiovascular assessment [44]. 
Expert recommendations
The indication of experts on groups of patients 
who would benefit from the use of Confirm Rx, 
are in line with the ESC Guidelines. The majority 
of experts also indicated that the use of Confirm 
Rx would contribute to improved diagnoses of 
the disease, patient safety, treatment efficiency, 
reduction in the frequency of appointments/hos-
pitalizations, treatment costs and occurrence of 
adverse cardiovascular events (including stroke 
and sudden cardiac death). In order to broaden 
patient access to Confirm Rx, experts primarily 
pointed to financing of the technology from public 
funds and development of recommendations for 
use of this technology.
Methods of intravascular imaging
Optical coherence tomography is an intravas-
cular visualization method based on the reflection 
of an infrared light beam, which has been used 
in interventional cardiology since the beginning 
of this century. This method is characterized by 
high resolution, up to 10 times higher than in-
travascular ultrasound (IVUS). It provides faster 
and longer image acquisition (compared to IVUS) 
and co-acquisition with angiography. Thanks to 
OCT, the accurate assessment of bifurcation and 
atherosclerotic plaque, thrombus diagnosis, early 
analysis of angioplasty effects, analysis of reste-
nosis and optimization of percutaneous coronary 
intervention (PCI) surgery are possible. It also 
provides three-dimensional reconstruction of 
blood vessels.
The recommendation on the use of OCT 
is included in the ESC Guidelines:
 — 2013 — regarding the management of stable 
coronary heart disease [45];
 — 2014 — concerning myocardial revasculariza-
tion [46];
 — 2018 — concerning myocardial revasculariza-
tion [47].
In current European clinical practice guide-
lines from 2018, OCT is recommended for stent 
optimization and was moved from class IIb to class 
IIa; e.g., OCT should be considered in the detection 
of stent-related mechanical problems, which lead 
to restenosis (class IIa) [47].
In the latest ILUMIEN OPTIS apparatus, 
which is used for intravascular imaging, the OCT 
method was integrated with the fractional flow 
reserve method. The integration of both methods 
in one platform enables the combination of two 
techniques to optimize coronary angioplasty proce-
dures in 1 patient. Due to the increase of frequency, 
it became possible to significantly accelerate the 
operation of the pull-back device in the system 
and significantly reduce the amount of contrast 
administered to the coronary artery. Owing to 
the small diameter of the Dragonfly catheter, it is 
possible to visualize tight changes in the coronary 
arteries. The axial resolution is only 15 μm with 
10 mm penetration of the light beam. The fractional 
flow reserve measurement module in the system 
operates in a wireless mode, thanks to which it can 
be used in many cardiac laboratories without the 
need for complicated installations [48].
Clinical evidence
The predominance of intravascular imaging with 
OCT over IVUS and angiography during PCI has been 
confirmed in clinical trials (Table 4) [49–50].
Other methods of intravascular imaging
Other methods of intravascular imaging in-
cluding:
 — magnetic resonance;
 — coronary angiography;
 — scintigraphy;
 — thermography (experimental).
Patient groups and indications in which the use 
of OCT will provide the greatest benefit:
 — young patients with unstable angina and bor-
der atherosclerotic lesions;
 — patients with left main trunk disease and/or 
the disease of major coronary vessels;
 — the assessment of the causes of thrombosis/ 
/restenosis;
 — the optimization of stent implantation (e.g. 
left coronary artery stump, bifurcations) — 
the ambiguous results of angiography, e.g. 
suspected thrombus, calcifications;
 — the evaluation of atherosclerotic plaque;
 — the evaluation of the effectiveness of PCI and 
stent apex.
Patient groups and indications in which the use 
of OCT will provide a potential benefit (in addition):
 — the diagnosis of acute coronary syndrome 
(including acute coronary syndrome without 
critical lesions, myocardial infarction (STEMI/ 
/NSTEMI, MINOCA) — the assessment of 
morphology of atherosclerotic lesions (dif-
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ferentiation between atherosclerotic plaque 
rupture and atherosclerotic plaque erosion, the 
diagnosis of unstable/atherosclerotic plaques);
 — coronary heart disease (the evaluation of 
coronary lesions);
 — the unclear results of coronarography;
 — bifurcation.
Expert recommendations
Experts have indicated that the use of OCT 
will primarily affect the reduction of the number of 
diagnostic tests and additional procedures. It will 
also contribute to improvements in the diagnosis of 
the disease, patient safety, treatment efficiency, the 
reduction of treatment costs, the occurrence of ad-
verse cardiovascular events and the improvement 
of the quality of interventions on coronary vessels.
Experts stated that patients have better re-
sults after OCT-assisted vs. non-assisted interven-
tion (similar conclusions for IVUS). At present in 
Poland, OCT is only reimbursed in ophthalmology, 
however, experts have indicated that in cardiol-
ogy OCT should be reimbursed and be equally as 
available as IVUS. This technology is reimbursed 
in most European Union countries. Both methods 
should therefore be the technologies to be used 
by choice, based on the operator’s decision. In 
order to broaden patient access to OCT, experts 
mainly pointed out recommendations for using this 
technology, obtaining financing from public funds 
and increasing the number of centers that use this 
technology.
Conclusions
The aim of this publication is to present the 
recommendations of leading experts in the field of 
cardiology and cardio-surgery, which are supported 
by clinical research results, regarding the use of 
cited innovative medical technologies and solu-
tions that lead to an increase of their availability 
for Polish patients.
When considering the country’s health policy 
in Poland, diseases of the cardiovascular system 
requires due attention given that they are an even 
more frequent cause of death than cancer. There is 
a great need to introduce new innovative technolo-
gies to improve health and QoL of Polish patients 
with cardiac problems. These are not only medical 
technologies that can be further used directly in 
the treatment of patients (LVAD, e.g.: HeartMate 3; 
the system for percutaneous repair of MR: Mitra-
Clip), but also diagnostic technologies that enable 
faster and more effective detection of the disease 
(ILR, e.g. Confirm Rx, PA pressure measurement 
systems: CardioMEMS) or increase the effective-
ness of treatment (OCT). The safety and effec-
tiveness of the described technologies have been 
confirmed in numerous scientific studies, not only 
in randomized clinical trials, but also in observa-
tional studies subsequent to the introduction of the 
technology into medical practice. Both guidelines 
and clinical recommendations can be based on this 
evidence. Scientific evidence for medical devices 
is also increasingly important for making decisions 
about their financing from public funds. The use 
of the above-mentioned technologies also affects 
a reduction in the number of additional medical ser-
vices, namely the number of hospitalizations, the 
reduction in the quantity of diagnostic tests or the 
demand and use of medicines, which can directly 
translate into a reduction of costs. Currently, the 
largest obstacle to the introduction of innovative 
health technologies is a lack of public funding, an 
incorrect calculation of costs associated with indi-
vidual technologies and a system that hinders the 
incorporation of innovative non-drug technologies 
into a guaranteed benefit package.
New diagnostic and therapeutic technologies 
in cardiology and cardiac surgery contribute im-
provement in patient QoL and an increase treat-
ment effectiveness. The use of these technologies 
also reduces direct costs, such as drug use, addi-
tional diagnostic tests and indirect costs such as 
additional hospitalizations, absence from work or 
permanent inability to work. It is therefore neces-
sary to increase their availability, primarily through 
the development of clinical recommendations, 
education of medical personnel and public funding.
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